Novo Nordisk Balances Pipeline Bets and Buybacks Against a 23% Slide
Published on 09/30/2026 at 20:50 | Editorial boerse-global.de
Novo Nordisk has spent the past week assembling the pieces of a longer-term growth story, pairing a fresh licensing alliance and new clinical readouts with an ongoing share repurchase program — even as its stock continues to lose ground on the Copenhagen and European exchanges.
The Danish drugmaker disclosed on September 24 a worldwide exclusive licensing and collaboration agreement with Sweden's Nanexa AB, centered on the latter's PharmaShell platform. The deal covers as many as five development programs spanning obesity, type-2 diabetes and additional cardiometabolic indications. For Novo, the appeal reaches beyond simply adding a technology: formulation and targeted drug release have become pivotal to advancing metabolic therapies, with novel delivery formats seen as a way to lift patient convenience and defend market share. Nanexa stands to receive up to EUR 1.165 billion in total, a figure that bundles upfront payments together with development and regulatory milestones worth EUR 615 million.
That partnership slots into a pipeline strategy that also leans heavily on CagriSema, the combination candidate whose study data were presented at the annual meeting of the European Association for the Study of Diabetes (EASD). In a 52-week trial involving adults with obesity, the drug candidate was associated with 22.4 percent weight loss versus placebo. Patients with type-2 diabetes likewise recorded meaningful weight reduction, and a supporting analysis pointed to preserved bone balance. Neurological measurements further indicated altered responses to calorie-dense foods, a signal that could help curb cravings. Novo views these findings as a key building block for securing the next generation of combination therapies in an increasingly crowded competitive field.
A Split Analyst View on Where the Shares Are Headed
Market watchers remain divided on the commercial outlook. Most industry analysts currently recommend a wait-and-see stance, with buy and sell ratings in the minority. The caution stems largely from mounting competitive pressure and uncertainty over long-term dominance in the GLP-1 segment. Price targets span a wide range: Rothschild & Co Redburn sets its objective at DKK 457, while Intron Health sees just DKK 200. Across all houses, the average 12-month target sits at DKK 312.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The divergence captures the tension Novo is navigating — blockbuster products continue to generate substantial revenue, yet rival pharma companies are sharpening the competition with alternative therapeutic approaches. On the equity market, that mix translated into another weak session, with the stock shedding 1.0 percent to trade at EUR 33.44. Year-to-date, the decline now stands at 24 percent.
External pipeline building is running in parallel with in-house research. Martin Holst Lange, the company's head of research and development, indicated according to Bloomberg that a novel weight-loss pill from the partnership with Hengrui Pharma could reach the market by 2030. Novo Nordisk has secured worldwide development and commercialization rights to the drug candidate HRS-1596 outside Greater China, a move aimed at adding oral alternatives to the portfolio down the road.
Prevention Spending and a Brand Refresh
Alongside its science bets, the group is expanding its global prevention work. On September 22, it announced an extension of its worldwide partnership with UNICEF targeting childhood overweight prevention, committing a total of USD 18 million between 2026 and 2030. The initiative is designed to reach more than 80 million children across seven focus countries with preventive offerings.
A revised brand identity accompanies this strategic direction. In day-to-day external communications, the group now operates under the shortened name Novo, complete with the Apis bull in its logo and a corporate culture dubbed The Novo Way. The official legal entity name remains unchanged as Novo Nordisk A/S.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Buyback Tranche Nears DKK 10 Billion
Cash continues to flow into repurchasing the company's own securities. In an interim update on Monday, management reported that as of September 25 the company had bought back a total of 35,379,179 of its own B shares. The average purchase price came in at DKK 280.95 per share, meaning exactly DKK 9,939,842,031 has been deployed since the tranche began on February 4. Cancelling the shares reduces the total number of outstanding units.
None of these measures has yet left a visible mark on the share price. The stock currently changes hands at EUR 33.74, down 23 percent since the start of the year and well below its 52-week high of EUR 54.86. Market participants are weighing the long-term earnings potential of the new technologies against the current headwinds buffeting the sector.
Ad
Novo Nordisk Stock: New Analysis - 30 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
